Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lo

Showing results (371-380 of 386) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaInês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
The Lancet. Digital Health|September 29, 2023
Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trialScott W Menzies, Christoph Sinz, Michelle Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
The Medical Journal of Australia|May 2, 2021
Australia in 2030: what is our path to health for all?Kathryn Backholer, Fran Baum, Summer M Finlay, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Pageof 39

Showing results (371-380 of 386) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaInês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
The Lancet. Digital Health|September 29, 2023
Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trialScott W Menzies, Christoph Sinz, Michelle Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanomaR V Rawson, C Adhikari, C Bierman, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
The Medical Journal of Australia|May 2, 2021
Australia in 2030: what is our path to health for all?Kathryn Backholer, Fran Baum, Summer M Finlay, et al.
Cancer Discovery|September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma SubtypesFelicity Newell, Peter A Johansson, James S Wilmott, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
JAMA Dermatology|April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous MelanomaSerigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
Pageof 39